Results 11,981-12,000 of 32,978 for speaker:Catherine Connolly
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I have a note somewhere - I think it is from Mr. Breen - stating a process of setting up a national office for open disclosure has commenced and the State Claims Agency has been invited to sit on the interview panel. Am I wrong about that?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: That is where that is coming from. Is it happening speedily enough?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: When are the interviews?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: In Mr. Breen's opening statement, he referred to a protocol and the necessity for a pre-action protocol for medical negligence cases. Has that been done?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Will Mr. Breen clarify that for me?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I have the document here. It refers to a pre-action protocol relating to clinical negligence and the making of regulations. Have the regulations been made?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Where does the fault lie for that?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Why have they not been made before now?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: How long will it take?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: We see so many good recommendations and reports and then there are delays in rolling them out. I ask the Chairman to indicate when I have five minutes left because I want to ask a number of questions on the thalidomide issue. A very good report was done by the Comptroller and Auditor General in 2012 on the clinical indemnity scheme. The issues raised then are very much alive today. One...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: An overall figure was given.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Those costs would not be identified then.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: There was a recommendation that there should be a system of spot-checking. Has that happened?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: What is the result?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: They are actual savings made.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: There are savings of 48% in 2017, which we have not looked at yet. We have looked at the figures for 2016. Mr. Breen is saying these are actual savings in legal costs.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: That raises a question. I realise the agency is not responsible for the costs and that it is the body making the saving. How is the bill coming in so high that the agency can achieve a 48% reduction in costs?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: How does the agency do that?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Agency officials go through that in minute detail. Is that correct?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: As a result, the agency has achieved a saving of 48%. Is that correct?